20/20 Biolabs, Inc.: Reduced the quorum required for a meeting of stockholders from a majority of the shares outstanding to one-third of the shares outstanding (effective 2026-05-19).
“On May 19, 2026, the Board of Directors of 20/20 Biolabs, Inc. (the “ Company ”) adopted Amendment No. 1 to the Company’s Amended and Restated Bylaws (the “ Amendment ”), pursuant to which Section 2.5 of the Company’s Amended and Restated Bylaws was amended to reduce the quorum required for a meeting of stockholders from a majority of the shares outstanding to one-third of the shares outstanding.”
Earnings Releases
20/20 Biolabs, Inc. reported the full year ended December 31, 2025 results: revenue $2.0 million, net income ($3.7) million.
“Revenue of $2.0 million for FY 2025, representing an increase of 17% over FY 2024. ● Deferred revenue totaled approximately $0.4 million as of December 31, 2025. ● Gross profit of $0.6 million for FY 2025, representing an increase of 68% over FY 2024. Gross margin was 29.6% in FY 2025, compared to 20.6% in FY 2024. ● Total operating expenses decreased 35% to $3.9 million in FY 2025 compared to $6.0 million in FY 2024. ● FY 2025 net loss improved 33% to ($3.7) million, compared to ($5.6) million in FY 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.